| Identification | Back Directory | [Name]
L-Cysteine, S-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]amino]-3-oxo-1-(1-piperidinylmethyl)propyl]- | [CAS]
1262034-38-7 | [Synonyms]
UNII-SOA52D3NLL
Dacomitinib metabolite M2
Dacomitinib cysteine conjugate
L-Cysteine, S-[3-[[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]amino]-3-oxo-1-(1-piperidinylmethyl)propyl]- | [Molecular Formula]
C27H32ClFN6O4S | [MOL File]
1262034-38-7.mol | [Molecular Weight]
591.1 |
| Hazard Information | Back Directory | [Uses]
Dacomitinib metabolite M1/2 is a potent inhibitor of both wild-type (WT) EGFR and the T790M mutation, demonstrating significant activity against acquired resistance mechanisms in EGFR-mutant non-small-cell lung cancer (NSCLC). | [References]
[1] Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? DOI:10.2147/DDDT.S52787 |
|
|